Enhanced Antiretroviral Therapy in Rhesus Macaques Improves RT-SHIV Viral Decay Kinetics

被引:9
作者
North, Thomas W. [1 ,2 ,3 ]
Villalobos, Andradi [1 ]
Hurwitz, Selwyn J. [1 ,2 ]
Deere, Jesse D. [3 ]
Higgins, Joanne [3 ]
Chatterjee, Payel [1 ,2 ]
Tao, Sijia [1 ,2 ]
Kauffman, Robert C. [3 ]
Luciw, Paul A. [3 ]
Kohler, James J. [1 ,2 ]
Schinazi, Raymond F. [1 ,2 ]
机构
[1] Emory Univ, Ctr AIDS Res, Sch Med, Atlanta, GA 30322 USA
[2] Atlanta Vet Affairs Med Ctr, Decatur, GA USA
[3] Univ Calif Davis, Davis, CA 95616 USA
关键词
SIMIAN IMMUNODEFICIENCY VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; NONHUMAN PRIMATE MODEL; COMBINATION THERAPY; ANIMAL-MODEL; HIV; TYPE-1; AIDS; PHARMACOKINETICS; ERADICATION;
D O I
10.1128/AAC.02522-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Using an established nonhuman primate model, rhesus macaques were infected intravenously with a chimeric simian immunodeficiency virus (SIV) consisting of SIVmac239 with the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase from clone HXBc2 (RT-SHIV). The impacts of two enhanced (four- and five-drug) highly active antiretroviral therapies (HAART) on early viral decay and rebound were determined. The four-drug combination consisted of an integrase inhibitor, L-870-812 (L-812), together with a three-drug regimen comprising emtricitabine [(-)-FTC], tenofovir (TFV), and efavirenz (EFV). The five-drug combination consisted of one analog for each of the four DNA precursors {using TFV, (-)-FTC, (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diaminopurine (amdoxovir [DAPD]), and zidovudine (AZT)}, together with EFV. A cohort treated with a three-drug combination of (-)-FTC, TFV, and EFV served as treated controls. Daily administration of a three-, four-, or five-drug combination of antiretroviral agents was initiated at week 6 or 8 after inoculation and continued up to week 50, followed by a rebound period. Plasma samples were collected routinely, and drug levels were monitored using liquid chromatography-tandem mass spectrometry (LC-MS-MS). Viral loads were monitored with a standard TaqMan quantitative reverse transcriptase PCR (qRT-PCR) assay. Comprehensive analyses of replication dynamics were performed. RT-SHIV infection in rhesus macaques produced typical viral infection kinetics, with untreated controls establishing persistent viral loads of >10(4) copies of RNA/ml. RT-SHIV loads at the start of treatment (V-o) were similar in all treated cohorts (P > 0.5). All antiretroviral drug levels were measureable in plasma. The four-drug and five-drug combination regimens (enhanced HAART) improved suppression of the viral load (within 1 week; P < 0.01) and had overall greater potency (P < 0.02) than the three-drug regimen (HAART). Moreover, rebound viremia occurred rapidly following cessation of any treatment. The enhanced HAART (four- or five-drug combination) showed significant improvement in viral suppression compared to the three-drug combination, but no combination was sufficient to eliminate viral reservoirs.
引用
收藏
页码:3927 / 3933
页数:7
相关论文
共 42 条
  • [1] HIV/AIDS: in search of an animal model
    Ambrose, Zandrea
    KewalRamani, Vineet N.
    Bieniasz, Paul D.
    Hatziioannou, Theodora
    [J]. TRENDS IN BIOTECHNOLOGY, 2007, 25 (08) : 333 - 337
  • [2] Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS
    Ansari, AA
    Mayne, AE
    Onlamoon, N
    Pattanapanyasat, K
    Mori, K
    Villinger, F
    [J]. IMMUNOLOGIC RESEARCH, 2004, 29 (1-3) : 1 - 17
  • [3] Nonhuman Primate Models for HIV Cure Research
    Apetrei, Cristian
    Pandrea, Ivona
    Mellors, John W.
    [J]. PLOS PATHOGENS, 2012, 8 (08):
  • [4] SENSITIVITY RESISTANCE PROFILE OF A SIMIAN IMMUNODEFICIENCY VIRUS CONTAINING THE REVERSE-TRANSCRIPTASE GENE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) TOWARD THE HIV-1-SPECIFIC NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS
    BALZARINI, J
    WEEGER, M
    CAMARASA, MJ
    DECLERCQ, E
    UBERLA, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (03) : 850 - 856
  • [5] 3'-AZIDO-2',3'-DIDEOXYURIDINE (AZDDU) - COMPARATIVE PHARMACOKINETICS WITH 3'-AZIDO-3'-DEOXYTHYMIDINE (AZT) IN MONKEYS
    BOUDINOT, FD
    SCHINAZI, RF
    GALLO, JM
    MCCLURE, HM
    ANDERSON, DC
    DOSHI, KJ
    KAMBHAMPATHI, PC
    CHU, CK
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (02) : 219 - 228
  • [6] AIDS - Re-emergence of HIV after stopping therapy
    Chun, TW
    Davey, RT
    Engel, D
    Lane, HC
    Fauci, AS
    [J]. NATURE, 1999, 401 (6756) : 874 - 875
  • [7] Latent reservoirs of HIV: Obstacles to the eradication of virus
    Chun, TW
    Fauci, AS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) : 10958 - 10961
  • [8] Costiniuk CT, 2013, AIDS RES HUM RETROV, V29, P266, DOI [10.1089/aid.2011.0343, 10.1089/AID.2011.0343]
  • [9] PHARMACOKINETICS OF 3'-AZIDO-3'-DEOXYTHYMIDINE AND ITS CATABOLITES AND INTERACTIONS WITH PROBENECID IN RHESUS-MONKEYS
    CRETTON, EM
    SCHINAZI, RF
    MCCLURE, HM
    ANDERSON, DC
    SOMMADOSSI, JP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (05) : 801 - 807
  • [10] Antiretroviral drugs
    De Clercq, Erik
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (05) : 507 - 515